BTEK holdings
As of , BTEK (iShares NASDAQ US Biotechnology UCITS ETF, ISIN IE00BYXG2H39) has 248 holdings on our record, together 100.2% of the fund; the ten largest make up 45.7%. iShares reports 250 positions in all. Weights are shares of the whole fund.
Largest holdings
| Rank# | Holding | Weight as a percentage of the fund |
|---|---|---|
| 1 | Gilead SciencesGILD | 8.25% |
| 2 | AmgenAMGN | 7.85% |
| 3 | Vertex PharmaceuticalsVRTX | 7.71% |
| 4 | ModernaMRNA | 5.30% |
| 5 | Regeneron PharmaceuticalsREGN | 4.95% |
| 6 | Revolution MedicinesRVMD | 2.86% |
| 7 | IlluminaILMN | 2.68% |
| 8 | Alnylam PharmaceuticalsALNY | 2.22% |
| 9 | BiogenBIIB | 2.19% |
| 10 | ArgenxARGX | 1.73% |
Source: iShares, holdings as published, as of
More of the portfolio
The fund publishes 250 holdings; the ten largest make up 45.7% of it. The fund's portfolio is also split by currency.
Create a free account to see the full holdings list and the currency, maturity and credit-quality breakdowns
Sign-up takes an email address. There is no card to enter and nothing to pay.
Where it invests
The whole portfolio by sector, country and type of asset, every line, as a share of the whole fund. Bonds, cash and positions the source does not classify are shown as they come, not guessed.
By sector
- Health Care99.8%
- Cash and derivatives0.2%
By type of asset
- Equity100.0%
- Cash and money market0.2%
More:BTEK: key facts, returns and chargesCompare what it holds with another fundHoldings overlapHow overlap is measured
Holdings and weights are as published by iShares on 29/09/2026 and change as the fund trades.